Gallium-68 PSMA-617

N/A

Report date: 2025/11/19 17:58:12

NME

Base Information

Drug NameGallium-68 PSMA-617

Drug Alias NamePSMA-617-[68Ga]225 Ac-PSMA-61768Ga-PSMA-61768Ga-DKFZ-61768Ga-DKFZ-PSMA -617 +[8]

ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68Ga +[5]

Mechanisms of ActionProstate-Specific Membrane Antigen inhibitorsPositron-emission tomography enhancersIonising radiation emitters

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Adenoid Cystic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesPeking Union Medical College Hospital

China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College Hospital

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsCarcinoma, Adenoid Cystic

Other Information

ATC CodeN/A